PP2A inactivation results from an increased expression of SET, which was induced by BCR-ABL in a dose- and kinase-dependent manner and, like BCR-ABL, progressively increases during the transition to CML-BC. The gene discussed is PTPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.